FindTrial
Sign In

Norditropin

DRUG7 trials

Sponsors

National Institute on Aging (NIA), Oregon Health and Science University, University of Aarhus, Novo Nordisk A/S, Children's Hospital Medical Center, Cincinnati

Conditions

Adult Growth Hormone DeficiencyDiabetes Mellitus Type IGrowth Hormone DeficiencyGrowth Hormone DisorderHealthy VolunteersKetoacidosisMetabolic SyndromeNoonan Syndrome

Phase 1

Growth Hormone Administration and the Human Immune System
CompletedNCT00663611
National Institute on Aging (NIA)Healthy Volunteers
Start: 2006-10-19End: 2014-10-06Updated: 2026-09-16
Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency
CompletedNCT03288103
Children's Hospital Medical Center, CincinnatiShort Stature
Start: 2018-02-01End: 2023-08-31Updated: 2024-07-30

Phase 2

Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children
CompletedNCT04513171
Xiamen Amoytop Biotech Co., Ltd.Growth Hormone Deficiency
Start: 2018-12-26End: 2023-07-10Updated: 2024-01-24

Phase 3

A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency
CompletedNCT03075644
Novo Nordisk A/SAdult Growth Hormone Deficiency, Growth Hormone Disorder
Start: 2017-03-03End: 2018-10-04Updated: 2020-11-23

Unknown Phase

Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome.
WithdrawnNCT00720616
Oregon Health and Science UniversityMetabolic Syndrome
Start: 2010-10-31End: 2012-12-31Updated: 2013-02-20
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.
CompletedNCT02077348
University of AarhusDiabetes Mellitus Type I, Ketoacidosis
Start: 2014-05-31End: 2015-09-30Updated: 2016-02-24
French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome
Enrolling by invitationNCT05308927
Novo Nordisk A/SNoonan Syndrome
Start: 2022-03-16End: 2028-03-17Target: 221Updated: 2025-09-25

Related Papers

Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial
Clinical Pharmacokinetics2024-07-011 citations
Insulin Signaling Is Preserved in Skeletal Muscle During Early Diabetic Ketoacidosis
The Journal of Clinical Endocrinology & Metabolism2023-08-091 citations
Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency
Pituitary2022-11-1514 citations
The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency
Frontiers in Endocrinology2022-08-118 citations
Impact of Acutely Increased Endogenous- and Exogenous Ketone Bodies on FGF21 Levels in Humans
Endocrine Research2020-10-195 citations
Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone
Clinical Endocrinology2020-06-3033 citations
MON-265 Once-Weekly Somapacitan in Japanese Adults with GH Deficiency Was Well Tolerated, with Similar Efficacy to Daily GH: A Randomized Trial
Journal of the Endocrine Society2020-04-01
Substrate metabolism, hormone and cytokine levels and adipose tissue signalling in individuals with type 1 diabetes after insulin withdrawal and subsequent insulin therapy to model the initiating steps of ketoacidosis.
2018-12-0114 citations